Media Resources

2016

Press Release: Report Reveals Danger Of TTIP Locking Europe & Us Into Higher Drug Prices, Failed Pharma Innovation Model

Fact or Fiction: What Healthcare Professionals Need to Know about Pharmaceutical Marketing in the European Union

56 Non-profit Organisations Question US State Department Pressure Against Global Access to Medicines Initiatives – Letter to US Secretary of State, John Kerry

Recommendations for EU Governments to Improve Access & Innovation of Needed Medicines

Measures That Reduced Price of Patented HIV Medicines Should Be Used to Safeguard Access to New Essential Medicines

WHA69 Intervention on Global Medicine Shortages and the Safety and Accessibility of Children’s Medication

HAI Co-signs Letter to Obama Administration Regarding Alleged U.S. Interference in Colombian Health Measure

Snakebite: Call for urgent global action to end death & suffering

HAI, KEI & STOPAIDS Statement on the WHO Consultative Expert Working Group on R&D

Measuring Medicine Prices, Availability, Affordability and Price Components (2nd Ed.)

Civil Society Urges Member States to Support the Dutch EU Presidency’s Vision on Access to Affordable Medicines

Assessing EU Funding for R&D for Poverty-related and Neglected Diseases

HAI Intervention at the United Nations High-Level Panel on Access to Medicines

Access to High-priced Medicines in Hospital Settings in Europe: A Study in Four European Countries

Study Finds Access to High-priced Medicines May Differ Across EU

Why You Should Be Concerned About TTIP and Access to Medicines

European CSOs Call for Rejection of EU Trade Secrets Directive

2015

Trilogue Negotiations on Commission’s Proposal for Trade Secrets Directive

Medicines Transparency Alliance (MeTA) Evaluation

Global Snakebite Initiative Appoints Health Action International as Secretariat

Multi-sectoral NGO Coalition Calls on Parliament to Defend Safeguards for Consumers, Journalists, Whistleblowers, Public Authorities and Workers

Empty Gestures – The EU’s Commitments to Safeguard Access to Medicines

HAI and MSF Report Shows European Commission’s Access to Medicines Commitments are ‘Empty Gestures’

EU medicines policy & access to medicines

Early Access to Medicines Marketing Authorisation Flexibilities Should Only Respond to Unmet Medical Needs, Must Protect Patient Safety

Direct Patient Reporting in the EU: A Snapshot of Reporting Systems in Seven Member States

Declaration of Public Interest Regarding Access to Imatinib (Glivec) in Colombia

Health Action International Opposes European Parliament’s ISDS Compromise in TTIP

EU Medicines Policy and Access to Medicines

HAI Sexual Harassment Policy